Safety and Efficacy of Ponatinib for Pulmonary Tumor Thrombotic Microangiopathy

Background

We evaluated the safety and efficacy of ponatinib, a multi-target tyrosine kinase inhibitor, for pulmonary tumor thrombotic microangiopathy (PTTM). Methods and results: We conducted a single-center, open-label, single-arm, prospective study; 3 patients associated with ovarian, breast, and gastric carcinomas were enrolled and received oral ponatinib for 2 weeks. All died from PTTM progression with no severe ponatinib-related adverse events.